[Measurement and clinical significance of serum DKK-1 and sRANKL levels in multiple myeloma].
To detect serum concentrations of Dickkopf-1 (DKK-1) and soluble receptor activator of nuclear factor-κB ligand (sRANKL) in patients with multiple myeloma (MM) and to investigate its clinical significance. Serum DKK-1, sRANKL, osteoprotegerin(OPG) and tartrate-resistant acid phosphatase 5b (TRACP-5b) levels were quantified in 30 newly diagnosed MM patients and 20 healthy control subjects by using sandwich ELISA. The serum DKK-1, sRANKL, OPG and TRACP-5b levels were significantly higher than those in the healthy controls (42.96 µg/L vs 5.33 µg/L, 1.83 pmol/L vs 0.79 pmol/L, 1799.30 pmol/L vs 822.40 pmol/L, 5.81 U/L vs 0.28 U/L, respectively; all P < 0.05). Serum levels of DKK-1 were positively correlated with sRANKL and TRACP-5b, respectively. Serum concentrations of DKK-1 and sRANKL were significantly elevated in stage III vs stages I and II according to International Staging System (ISS) (46.33 µg/L vs 37.91 µg/L, 2.26 pmol/L vs 1.19 pmol/L, respectively, all P < 0.05). Serum concentrations of DKK-1, sRANKL and TRACP-5b were significantly higher in patients with more than 3 lytic bone lesions than those with only 1-3 lytic bone lesions (46.30 µg/L vs 31.98 µg/L, 2.18 pmol/L vs 0.69 pmol/L, 6.02 U/L vs 5.13 U/L, all P < 0.05). MM patients have increased serum DKK-1, sRANKL, OPG and TRACP-5b levels as compared with the healthy controls. Serum concentrations of DKK-1 and sRANKL have close relationship with MM stage and lytic bone disease.